nbtxr3
nbtxr3: developed by 1 company · 2 clinical trials tracked.
nbtxr3 evidence translation
What we can confirm
2 tracked trials
What it means
Source-backed records connect nbtxr3 to LIANY; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could nbtxr3 → LIANY affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 1 study sponsors
Related indications
locally advanced head and neck ("H&N") squamous cell carcinomaMetastatic Renal Cell Carcinoma
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| LianBio (LIANY) locally advanced head and neck ("H&N") squamous cell carcino… | Phase 3 |
Clinical Trials (2)
NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer
Primary endpoint: Safety and Adverse Events (AEs)
Interventionalopen40 targetStarted 2026-03Completion 2030-081 site · United StatesM.D. Anderson Cancer Center
A Phase I Dose Escalation / Dose Expansion Study of NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
Primary endpoint: [Dose Escalation Part]: Determination of the Recommended Dose
Interventionalopen145 targetStarted 2019-01Completion 2027-0813 sites · United StatesNanobiotix
Frequently asked questions
Who is developing nbtxr3?
nbtxr3 is being developed by LianBio.
How many clinical trials involve nbtxr3?
BioSniper tracks 2 clinical trials involving nbtxr3.